EXPLAINER | How Aspen aims to make enough Covid-19 vaccines for every single person in Africa

accreditation
Share your Subscriber Article
You have 5 articles to share every month. Send this story to a friend!
0:00
play article
Subscribers can listen to this article
Aspen’s deputy group chief executive Gus Attridge.
Aspen’s deputy group chief executive Gus Attridge.
Picture supplied

Aspen Pharmacare, Africa’s largest pharmaceutical company, set itself a production target of 1.3 billion Covid-19 vaccine doses - one potentially for every person in Africa, following a licence agreement with Johnson & Johnson.

Aspen currently has a deal with Johnson & Johnson to package and fill its vaccine vials, and on Tuesday, announced yet another important agreement with the multinational that will see the local pharmaceutical company manufacture and sell its own Covid-19 vaccine in Africa, dubbed Aspenovax. 

Aspen will be able to manufacture its own brand of the vaccine owing to Johnson & Johnson granting the group an intellectual property licence. 

Support independent journalism
Subscribe to News24 for just R75 per month to read all our investigative and in-depth journalism. You can cancel any time.
Subscribe
Already a subscriber? Sign in
Rand - Dollar
15.36
-0.8%
Rand - Pound
20.68
-0.4%
Rand - Euro
17.26
-0.1%
Rand - Aus dollar
10.91
+0.0%
Rand - Yen
0.13
-0.1%
Gold
1,818.88
-1.6%
Silver
23.54
-1.1%
Palladium
2,332.00
+5.9%
Platinum
1,035.50
+0.6%
Brent Crude
88.20
+2.2%
Top 40
67,364
+2.2%
All Share
73,797
+2.0%
Resource 10
75,253
+3.2%
Industrial 25
91,472
+1.8%
Financial 15
14,925
+0.8%
All JSE data delayed by at least 15 minutes Iress logo
Company Snapshot